Pacira BioSciences Inc
PCRXHealthcare|Drug Manufacturers - Specialty & Generic|USA
$25.47
-0.01 (-0.04%)
DCF (FCF)
$43.62
Tangible Book
$7.15
Graham Number
$18.67
Earnings Power
$19.49
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
766.38,
826.04,
931.04,
924.96,
932.05
],
"ebit_estimate": [
176.84,
201.77,
349.43,
262.95,
95.39
],
"ebitda_estimate": [
184.48,
227.33,
432.5,
280.5,
null
],
"net_income_estimate": [
126.05,
151.02,
216.16,
199.54,
179.66
],
"per_share_eps_estimate": [
0.5,
2.79,
7.35,
3.98,
3.6
],
"eps_nri_estimate": [
2.88,
3.65,
4.54,
4.2,
3.78
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
16.66,
22.24,
51.54,
null,
null
],
"pretax_income_estimate": [
167.89,
195.81,
300.56,
263.91,
null
],
"operating_cash_flow_per_share_estimate": [
5.26,
6.39,
8.16,
null,
null
],
"roa_estimate": [
9.4,
10.9,
15.5,
null,
null
],
"roe_estimate": [
17.3,
19.4,
22.4,
null,
null
],
"gross_margin_estimate": [
78.85,
80.55,
85,
82.6,
null
],
"operating_cash_flow_estimate": [
215.19,
261.42,
333.83,
null,
null
],
"pettm_estimate": [
50.94,
9.15,
3.47,
6.4,
7.08
],
"long_term_growth_rate_mean": 20.36,
"long_term_revenue_growth_rate_mean": "8.54",
"future_per_share_eps_estimate_growth": 274.31,
"future_eps_nri_estimate_growth": 20.36,
"future_revenue_estimate_growth": 8.54,
"future_ebit_estimate_growth": 28.56,
"future_ebitda_estimate_growth": 31.43,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 20.8,
"future_pretax_income_estimate_growth": 140.93,
"future_book_value_per_share_estimate_growth": 43.93,
"future_roa_estimate_growth": 20.78,
"future_roe_estimate_growth": 10.63,
"future_gross_margin_estimate_growth": 5.55,
"future_operating_cash_flow_per_share_estimate_growth": 34.4
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
190.82,
190.68,
208.68,
183.01,
202.43,
202.09,
222.02
],
"ebit_estimate": [
40.05,
43.9,
43.95,
null,
null,
null,
null
],
"ebitda_estimate": [
40.73,
46.7,
51.43,
62.5,
67.6,
69.3,
74.5
],
"net_income_estimate": [
27.32,
32.88,
35.16,
29.31,
32.69,
35.61,
38.4
],
"per_share_eps_estimate": [
0.76,
0.87,
0.7,
0.18,
0.29,
0.37,
0.46
],
"eps_nri_estimate": [
0.65,
0.76,
0.87,
0.81,
0.9,
0.88,
1.01
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
15.88,
15.92,
16.43,
17.15,
17.82,
18.59,
19.44
],
"pretax_income_estimate": [
40.05,
45.4,
42.95,
null,
null,
null,
null
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
0.4,
0.8,
0.7,
0.6,
0.9,
1.1,
1.4
],
"roe_estimate": [
0.7,
1.5,
1.3,
1.1,
1.6,
2,
2.3
],
"gross_margin_estimate": [
80.4,
80.4,
76.1,
78,
79,
79,
79
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
10.15,
12.49,
16.54,
19.59,
null,
null,
null
],
"long_term_growth_rate_mean": 20.36,
"long_term_revenue_growth_rate_mean": "8.54",
"future_per_share_eps_estimate_growth": 274.31,
"future_eps_nri_estimate_growth": 20.36,
"future_revenue_estimate_growth": 8.54,
"future_ebit_estimate_growth": 28.56,
"future_ebitda_estimate_growth": 31.43,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 20.8,
"future_pretax_income_estimate_growth": 140.93,
"future_book_value_per_share_estimate_growth": 43.93,
"future_roa_estimate_growth": 20.78,
"future_roe_estimate_growth": 10.63,
"future_gross_margin_estimate_growth": 5.55,
"future_operating_cash_flow_per_share_estimate_growth": 34.4
}